Key facts
- This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 21 Jan 2025, 16:02.
Pascal Deschatelets - 17 Jan 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- APLS
- Reported as of
- 17 Jan 2025
- Net transaction value
- -$22,469
- SEC form
- 4
- Accepted by SEC
- 21 Jan 2025, 16:02:18 UTC
- Prior SEC filing
- 14 Jan 2025
- Next SEC filing
- 23 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 21 Jan 2025.
Change
- Previous filing in this sequence was filed on 14 Jan 2025.
- Current net transaction value: -$22,469.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLS
transaction
Common Stock
Sale
- Transaction value
- $22,469
- Shares
- -750
- Change %
- -0.07%
- Price
- $29.96
- Shares after
- 1,137,445
- Date
- 17 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
APLS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +15,045
- Change %
- +1.3%
- Price
- $0.000000
- Shares after
- 1,152,490
- Date
- 21 Jan 2025
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2025.
Footnote F2
This represents a Restricted Stock Unit award granted on January 21, 2025 that vest 25% annually over four years from grant date subject to continued service.